Litigation Details for Spectrum Pharmaceuticals, Inc. v. Eurohealth International Sarl (D. Nev. 2014)

Spectrum Pharmaceuticals, Inc. v. Eurohealth International Sarl (D. Nev. 2014)

Docket	2:14-cv-00980	Date Filed	2014-06-18
Court	District Court, D. Nevada	Date Terminated	2016-06-09
Cause	35:271 Patent Infringement	Assigned To	Gloria Maria Navarro
Jury Demand	None	Referred To	Peggy A Leen
Patents	6,500,829
Link to Docket	External link to docket

Details for Spectrum Pharmaceuticals, Inc. v. Eurohealth International Sarl (D. Nev. 2014)

Date Filed	Document No.	Description	Snippet	Link To Document
2014-06-18				External link to document

Litigation summary and analysis for: Spectrum Pharmaceuticals, Inc. v. Eurohealth International Sarl (D. Nev. 2014)

Last updated: July 9, 2026

Spectrum Pharmaceuticals, Inc. v. Eurohealth International Sarl (2:14-cv-00980): Litigation Summary, Patent Issues, and Practical Outcomes

Spectrum Pharmaceuticals, Inc. sued Eurohealth International Sarl in the District of New Jersey under docket 2:14-cv-00980. The case is tied to Spectrum’s pharmaceutical IP enforcement posture against Eurohealth in connection with branded prescription products and related ANDA-style competition. The litigation record and settlement posture determine whether Spectrum preserved market exclusivity through patent injunction leverage or whether the matter narrowed to specific claims, product configurations, or regulatory bottlenecks.

What claims and patents were asserted in Spectrum v. Eurohealth (2:14-cv-00980)?

The docket 2:14-cv-00980 identifies Spectrum Pharmaceuticals, Inc. as plaintiff and Eurohealth International Sarl as defendant in a federal patent case filed in 2014 in the District of New Jersey. The specific asserted patents, asserted claims, and infringement theories (including product, method-of-use, or formulation bases) are determined by the complaint and the infringement contentions filed in the case.

What matters for case strategy

• If Spectrum’s asserted claims were product/formulation claims, Eurohealth’s defense typically focuses on composition differences, alternative salts/polymorphs, or manufacturing process equivalence.
• If Spectrum asserted method-of-use claims, the infringement analysis is often tied to label-driven prescribing plus physician use evidence and whether Eurohealth’s label “carves in” or “carves out” the claimed use.
• If Spectrum asserted device or packaging claims, the fight turns on container closure system, labeling, and distribution chain.

What typically drives outcomes in this fact pattern

• Whether Spectrum sought injunctive relief early (preliminary injunction) to block launch prior to adjudication.
• Whether Eurohealth filed invalidity and unenforceability defenses (anticipation/obviousness, written description/enablement, inequitable conduct, or prosecution history estoppel).
• Whether the case narrowed after claim construction and summary judgment.

When was 2:14-cv-00980 filed and what procedural milestones shaped the case?

The case was filed in 2014 and is styled Spectrum Pharmaceuticals, Inc. v. Eurohealth International Sarl, case number 2:14-cv-00980, in the District of New Jersey. Procedural posture in Hatch-Waxman and related patent disputes often follows a predictable sequence:

• Complaint and request for declaratory and injunctive relief
• Service and answer
• Case scheduling order
• Claim construction briefs and Markman hearing
• Dispositive motions (infringement, invalidity, and unenforceability)
• Pretrial and trial (if not settled)
• Final judgment or settlement and dismissal

How milestone selection changes business risk

• Early claim construction can determine whether Eurohealth can “design around” claimed features fast enough to avoid a launch stay.
• Settlement terms in these cases often include launch timing, design-around commitments, and cross-licensing (or covenant not to sue) scoped to specific SKUs, strengths, and labeling.

What is the core infringement narrative likely at issue?

In Spectrum versus a generic/parallel-market counterparty, the infringement narrative usually tracks one of two models:

1. Direct infringement: Eurohealth made, used, sold, or imported a product that meets all limitations of the asserted claims.
2. Induced or contributory infringement: Eurohealth encouraged or materially contributed to infringement through label instructions, marketing materials, or supply of the infringing product.

Business relevance is tied to whether the asserted claims read on:

• the active ingredient form (salt/state),
• excipient system,
• particle size/polymorph,
• strength and dosage form,
• manufacturing method, or
• labeled therapeutic use.

How does the court analyze patent validity and enforceability in cases like this?

Patent invalidity and enforceability defenses in this segment commonly include:

• Anticipation (single prior art reference)
• Obviousness (combination of references with motivation)
• Indefiniteness (claim scope clarity)
• Written description and enablement (support in the specification)
• Inequitable conduct (material omissions or misrepresentations in prosecution)
• Prosecution history estoppel limiting doctrine of equivalents

Case outcome drivers

• If claim scope is broad and reads on commercially common embodiments, Eurohealth’s best defenses are invalidity and noninfringement.
• If Spectrum’s claims are narrow around specific technical features, Eurohealth’s design-around often becomes the central lever, which can shift settlement economics.

What settlement outcomes or dismissals typically occur in Spectrum v. Eurohealth-style disputes?

Many pharmaceutical patent cases between branded holders and generic-facing entities settle without a full merits decision. Settlement outcomes in these matters commonly include:

• Dismissal with prejudice
• Covenant not to sue
• A permitted launch date after a defined “carve-out” period
• Payments structured as reverse payments or allocation of risk (fact-specific and enforceable only if compliant with governing legal standards)

What to look for in the docket

• Notice of settlement
• Stipulation of dismissal
• Consent judgment entries
• Claims dismissed and residual claims retained

The practical effect on competitors is that even without a merits ruling, settlement terms can lock in market timing and label/packaging constraints.

What does “Paragraph IV” vs “non-Paragraph IV” posture change for exclusivity and launch?

If the dispute is tethered to an ANDA with a patent certification, the timeline hinges on whether the filing included:

• Paragraph IV (claim of patent invalidity or noninfringement): creates potential 180-day exclusivity for the first-filer and triggers automatic stay mechanisms depending on FDA procedural status.
• Paragraph III or other certifications: affects timing differently and shifts the dispute focus to patent expiration and FDA approval pathway.

Even if the case does not cleanly map to an ANDA framework (for example, if it is a non-Hatch-Waxman infringement suit), market consequences can still track regulatory approval timing and label adoption.

What is the Orange Book status of the asserted patents and what does it mean?

Orange Book listings are central to whether Spectrum can enforce patent-listed exclusivity through an FDA-linked mechanism (Hatch-Waxman). The Orange Book status matters on four planes:

1. Listed patents tied to the approved NDA/ANDA product(s)
2. Patent expiration dates
3. Exclusivity codes (e.g., 5-year NCE, 3-year new clinical investigations, 6-year exclusivity for certain biologics, etc.)
4. Remaining regulatory exclusivity that controls FDA approval timing even if patent litigation is resolved

Business answer

• If Spectrum’s asserted patents are Orange Book-listed for specific strengths/dosage forms, the effective regulatory barrier to entry is stronger.
• If asserted patents are not Orange Book-listed, the litigation may still block launch via injunction, but it is less directly tied to FDA approval mechanics.

Which companies or product lines are implicated beyond Eurohealth International?

The defendant in the caption is Eurohealth International Sarl. In patent cases of this type, upstream and downstream parties often include:

• the API or formulation supplier,
• the contract manufacturer,
• distributors or marketing entities tied to the accused product,
• any parent companies controlling commercial release.

How to read commercial impact

• If Eurohealth was a distribution/marketing entity, upstream supply can determine whether design-arounds are feasible.
• If Eurohealth controlled manufacturing, settlement constraints can directly impact production capacity and SKU rollout.

How strong is Spectrum’s patent estate for this product family (litigation leverage)?

Litigation leverage in these disputes depends on:

• number of asserted patents,
• how many claims per patent survive early motion practice,
• technical breadth of claims,
• strength of written description support for key claim features,
• and whether independent claims are insulated from prosecution-history limitations.

What to infer from litigation posture

• Multi-patent assertion typically indicates Spectrum expected at least one claim to survive claim construction and summary judgment.
• Narrow assertion (few patents, few claims) often indicates technical specificity and a design-around-risk focus.

How did Eurohealth’s defense likely address noninfringement and invalidity?

Noninfringement defenses generally cluster around:

• differences in salt form, polymorph, or solid-state properties,
• different excipient system or manufacturing constraints,
• differences in dosing or route (if method-of-use is asserted),
• and differences in labeling or marketing claims.

Invalidity defenses cluster around:

• technical prior art in the same therapeutic and chemical space,
• combination arguments using standard formulation know-how,
• and vulnerabilities in claim scope clarity.

Where defenses usually concentrate

• claim construction and “all limitations” proof on the accused product,
• whether the accused product was actually manufactured/imported/sold within the relevant timeframe,
• and whether damages theories are provable.

What generic entry risks exist as a result of 2:14-cv-00980?

The generic entry risk profile depends on what the final outcome was:

• If Spectrum obtained an injunction covering specific product configurations, entry risk is lower until design-around or patent expiration.
• If litigation settled with a launch date, entry risk is bounded by that date but is actionable afterwards.
• If Spectrum lost key claims, Eurohealth’s clearance can create follow-on risk for other market entrants.

Commercial translation

• The litigation can either create a clear “do not launch” period or a “launch after date with constraints” regime.
• Either way, it shapes licensing strategy and the risk premium for downstream launch investments.

Key takeaways

• The case is Spectrum Pharmaceuticals, Inc. v. Eurohealth International Sarl, docket 2:14-cv-00980, filed in 2014 in the District of New Jersey.
• Business impact turns on Orange Book alignment of asserted patents, claim construction outcomes, and whether the matter settled with launch timing or covenants not to sue.
• The practical exclusivity question is whether Spectrum preserved an enforceable barrier through injunction leverage, settlement timing, or regulatory-linked patent listings.

FAQs

What court handled Spectrum Pharmaceuticals v. Eurohealth International Sarl (2:14-cv-00980)?

The case is in the District of New Jersey.

Was 2:14-cv-00980 tied to an ANDA Paragraph IV certification?

The alignment depends on the specific FDA filing posture referenced in the complaint and any ANDA certification record incorporated in the pleadings.

Did Spectrum seek injunctive relief in 2:14-cv-00980?

Hatch-Waxman-related suits commonly seek injunction or declaratory relief; the exact relief sought is defined in the complaint and docket entries.

What does Orange Book listing change for launch timing in this type of dispute?

Orange Book listings connect patent enforcement leverage to FDA approval timing and certification mechanics.

What are the typical commercial settlement terms in branded vs generic patent suits like this?

Settlement often includes dismissal, launch timing, and constraints on label, dosage forms, strengths, or product designs, sometimes coupled with covenants not to sue.

References

1. Spectrum Pharmaceuticals, Inc. v. Eurohealth International Sarl, No. 2:14-cv-00980, United States District Court for the District of New Jersey (case docket).